Tweet

Treatment For Feline Leukemia (FeLV) And Immunodeficiency Virus (FIV) Receives License Renewal From USDA

Author: Imulan
Posted: Monday 21st December, 2009. 00:00:00

T-Cyte Therapeutics, Inc. announced their conditional license renewal from the United States Department of Agriculture for Lymphocyte T-Cell Immunomodulator (LTCI). LTCI is the first and only approved treatment aid in the United States for cats infected with feline leukemia virus (FeLV) and immunodeficiency virus (FIV). LTCI is licensed and distributed by IMULAN BioTherapeutics; a US based veterinary immunobiology company. Conditional licenses are granted by the USDA for products which have passed safety and purity testing and where there is an emergency need or no other product available. LTCI is undergoing additional efficacy and potency studies.

This article has been viewed 1270 times.

 

Comments about this article